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Abstract
Background: Methionine sulfoxide reductases (Msrs) are enzymes that catalyze the reduction of oxidized
methionine residues. Most organisms that were genetically modified to lack the MsrA gene have shown
shortening of their life span. Methionine sulfoxide reductases B (MsrB) proteins codified by three separate
genes, named MsrB1, MsrB2, and MsrB3, are included in the Msrs system. To date, the mechanisms
responsible for the transcriptional regulation of MsrB genes have not been reported. The aim of this study
was to investigate the regulation of MsrB1 selenoprotein levels through transcriptional regulation of the
MsrB1 gene in MDA-MB231 and MCF-7 breast carcinoma cell lines.
Results: A MsrB1 gene promoter is located 169 base pairs upstream from the transcription start site. It
contains three Sp1 binding sites which are sufficient for maximal promoter activity in transient transfection
experiments.
High levels of MsrB1 transcript, protein and promoter activity were detected in low metastatic MCF7
human breast cancer cells. On the contrary, very low levels of both MsrB1 transcript and promoter activity
were detected in the highly metastatic counterpart MDA-MB231 cells.
A pivotal role for Sp1 in the constitutive expression of the MsrB1 gene was demonstrated through
transient expression of mutant MsrB1  promoter-reporter gene constructs and chromatin
immunoprecipitation experiments.
Since Sp1 is ubiquitously expressed, these sites, while necessary, are not sufficient to explain the patterns
of gene expression of MsrB1 in various human breast cancer cells. MDA-MB231 cells can be induced to
express MsrB1 by treatment with 5-Aza-2'-deoxycytidine, a demethylating agent. Therefore, the MsrB1
promoter is controlled by epigenetic modifications.
Conclusion: The results of this study provide the first insights into the transcriptional regulation of the
human MsrB1 gene, including the discovery that the Sp1 transcription factor may play a central role in its
expression. We also demonstrated that the MsrB1  promoter activity appears to be controlled by
epigenetic modifications such as methylation.
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Background
The methionine sulfoxide reductases enzymes (Msrs)
family contains proteins that can reduce both free and
protein-linked oxidized methionine residues. To date, the
two Msr enzymes that reduce the epimeric forms of
methionine sulfoxide Met(O) in proteins are referred to as
MsrA and MsrB: they catalyze the reduction of methio-
nine-S-sulfoxide (Met-SO) and methionine-R-sulfoxide
(Met-RO), respectively [1-3]. Several authors reported that
MsrA and MsrB require reduced thioredoxin as the natural
reducing system, although DTT can be used in vitro
[1,3,4]. As reported by Sagher et al., thioredoxin is a poor
reducing agent for both hMsrB2 and hMsrB3 [5]. How-
ever, in the presence of selenocystamine, the thioredoxin
reducing system is very effective with MsrB enzymes. A
cysteine residue in the N-terminal region of the MsrB1 is
important for the thioredoxin-recycling process of the
MsrB1 [6]. Recently, a thionein derived from metal-
lothionein and identified in bovine liver was shown to
support Msr activity in absence of either thioredoxin or
DTT (7).
Oxidation of methionines may affect protein function
and was implicated in several processes, such as oxidative
stress, accelerated aging, and neurodegenerative diseases
[8-12]. MsrA has been studied in detail for several years
and is well characterized structurally and functionally.
The importance of this enzyme was highlighted by several
studies. Escherichia coli MsrA mutant seemed to be more
sensitive to oxidative damage than the parent strain [13].
Abolishing the MsrA gene in yeast caused enhanced accu-
mulation of methionine oxidation, while shortening their
survival rate in response to oxidative stress [14,15]. Msra-
knockout mice had a shorter life span, were more sensitive
to hyperbaric oxygen, and had a neurological defect that
resulted in abnormal walking [16]. Overexpression of
MsrA nearly doubled the life span in Drosophila mela-
nogaster [17]. Moreover, MsrA activity, as well as gene and
protein expression, decreased as a function of age [18,19].
Human genome contains one single MsrA gene and three
separate genes named MsrB1, MsrB2, and MsrB3: the latter
codifying for MsrB3A and MsrB3B. These proteins have a
specific sub-cellular localization: MsrB1 is located in the
cytoplasm and nucleus, MsrB2 and MsrB3B in mitochon-
dria and MsrB3A in the endoplasmic reticulum [20].
MsrB1 is a selenoprotein also known as selenoprotein R
or selenoprotein X. Selenocysteine (Sec) plays a crucial
role in MsrB1 enzyme activity [6,20,21]. MsrB1 possessed
a 100-fold higher activity than its cysteine mutant form.
Moreover, substitution of catalytic cysteine with Sec
resulted in more than 100-fold increased activities in the
non-selenoprotein MsrB2 and MsrB3[22]. Among the
MsrB proteins, MsrB1 possessed the highest specific activ-
ity and was considered, together with MsrA, the enzyme
that contributed significantly to the reduction of methio-
nine sulfoxides in cells [20].
The overproduction of reactive oxygen species (ROS) can
result in various deleterious effects. Aerobic organisms
have developed a number of cellular defences as a protec-
tion against these harmful ROS [23]. The classical cellular
defence against ROS includes enzymes such as catalase
(CAT), superoxide dismutases (SOD), and glutathione
peroxidase (GPX). In recent years, the Msr system, which
can repair oxidative damage to proteins, has been added
to this important "antioxidant triad". The Msr system is
based on enzymes that can reduce both free and protein-
linked oxidized methionine residues; thus this system is
now considered an important defence mechanism against
oxidative damage [1,9,24,25].
Despite the importance of Msr enzymes in the defence
system against oxidative damage, little is known about the
transcriptional regulation of their genes. Moskovitz et al.
reported that mRNA and protein levels of MsrB1 were
associated with MsrA expression, as well as to selenium
supply [26]. However, the mechanism by which MsrA
might have a role in MsrB1 regulation has not been eluci-
dated.
We recently reported the identification and analysis of the
promoter region of the human MsrA gene [27]. The MsrA
expression appeared to be different in several human can-
cer cell lines and MsrA gene promoter analysis showed a
cell-specific transcriptional regulation of this gene [27].
In this study, we investigated the transcriptional regula-
tion of the MsrB1 gene in human breast cancer cells. We
found different MsrB1 expression levels in cancer cell lines
derived from the same tissue. We determined the tran-
scription start site (TSS) and isolated the 5'-flanking
region of the MsrB1 gene. We showed that multiple Sp1
binding sites were required for promoter activity and the
observed difference in MsrB1 gene expression could be
explained as a consequence of epigenetic modifications.
Results
MsrB1 transcript and protein are differentially expressed 
in breast cancer cell lines
In order to evaluate the relative levels of MsrB1 transcript
in both MDA-MB231 and MCF7 cells, RT-PCR was con-
ducted using 1 µg of total RNA samples obtained from
these cells. As shown in Figure 1, a lower level of MsrB1
transcript was detected in RT-PCR products obtained
using total RNA extracted from MDA-MB231 cells com-
pared to those obtained from MCF7 cells. Levels of MsrB1
protein detected by Western blot analysis were consistent
with the MsrB1 transcript data (Figure 1). In fact, a lowerBMC Molecular Biology 2007, 8:39 http://www.biomedcentral.com/1471-2199/8/39
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level of MsrB1 protein was detected in crude extracts
obtained from MDA-MB231 cells versus MCF7 cells, sug-
gesting a different MsrB1  transcriptional regulation in
these human breast cancer cell lines.
Identification of transcription start site
To identify the transcription start site (TSS) of the MsrB1
gene, we performed 5' RACE analysis using total RNA iso-
lated from MCF7 cells. The analysis was performed using
two reverse oligonucleotides derived from the 5'-UTR
region (Table 1) and two adapter primers provided with
the kit for the primary and nested PCR. A weak smear on
agarose gel was observed in the first PCR with outer
primer GeneRacer™ 5' Primer and reverse primer RACE-1,
using the total RNA from MCF7 cells. The primary PCR
products were used as templates for nested PCR using
GeneRacer™ 5' Nested Primer and RACE-2 nested primer.
Agarose gel electrophoresis resolved the 5'-RACE-nested
reaction product into a single DNA fragment (Figure 2)
which was then cloned. The sequencing of six different
randomly-selected clones showed the same sequence (Fig-
ure 2). The TSS was identified by sequence analysis and
mapped 90 bp upstream of the first ATG translation
codon.
MsrB1 promoter activity in transient transfection of 
different cell types
On the basis of the TSS position, a 1403 bp fragment of
human genomic DNA (-1276/+127) was obtained by
PCR. The sequence of the 5'-flanking region of the MsrB1
gene was analysed using TFSEARCH software for the pres-
ence of transcription binding sites. The MsrB1 5'-flanking
region revealed no canonical TATA and/or CAAT boxes,
but did contain several putative binding sites for Sp1 and
showed a high content of CpG islands. To map promoter
activity of the 5'-flanking region of the MsrB1 gene, vari-
ous 5' progressive deletions excluding each Sp1 binding
site starting from -1276 were prepared. The 1403 bp DNA
fragment was subcloned, sequenced and used as template
to make PCR products of lengths between -1276/+127 (P-
1403) and -38/+127 (P-165). These DNA-fragments were
subcloned into the promoterless pGL3 Basic reporter plas-
mid and the resulting P-1403, P-296, P-250, P-203, and P-
165 constructs were analysed by sequencing to ensure
fidelity of amplification. The human MCF7 and MDA-
MB231 cells were chosen as breast cancer cell models for
the analysis of the MsrB1  promoter activity. Figure 3
shows the relative luciferase activities of reporter con-
structs transfected in these cells. Maximal promoter activ-
ity was detected, using the P-296 construct, 169 bp
(containing the three Sp1 sites) from the TSS. Constructs
longer than 296 bp had reduced activity suggesting the
presence of possible cis-elements recognized by transcrip-
tion factors. However, computational analysis
(TFSEARCH) of the MsrB1 promoter did not show the
presence of distinct upstream inhibitory elements. We
detected very low levels of MsrB1 mRNA in MDA-MB231
cells and in accordance a very low promoter activity
detected in these cells (Figure 1).
Site-directed mutagenesis of the MsrB1 promoter
The contribution of Sp1 transcription factor in MsrB1 reg-
ulation was assessed by site-directed mutagenesis of their
binding sites within the MsrB1  promoter-reporter gene
constructs (P-203 and P-296). On the basis of the tran-
sient transfection experiments reported above, we focused
our attention on the Sp1 sites named Sp1E and Sp1C (Fig-
Analysis of MsrB1 transcript and protein levels in MCF7 and  MDA-MB231 breast cancer cell lines Figure 1
Analysis of MsrB1 transcript and protein levels in 
MCF7 and MDA-MB231 breast cancer cell lines. (A) 
Ethidium bromide-stained gel showing the level of MsrB1 
transcript between MCF7 and MDA-MB231 cells. GAPDH 
was used as the control. The MsrB1 transcript levels in 
MCF7 and MDA-MB231 cells were analysed using Chemi 
Doc System (Bio-Rad) and normalized by GAPDH signal 
intensities of the corresponding lanes. The data are reported 
as mean ± S.D. of three independent experiments; * P < 
0.001. (B) Immunoblotting of MCF7 and MDA-MB231 
extracts with a mouse monoclonal anti-MsrB1. The MsrB1 
protein (13 kDa) levels in MCF7 and MDA-MB231 cells were 
analysed using Chemi Doc System (Bio-Rad) and normalized 
by β-actin (42 kDa) signal intensities of the corresponding 
lanes. Values are reported as mean ± S.D. of at least five dif-
ferent immunoblotting experiments; ** P < 0.005.
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ure 3). Reporter constructs containing mutated sequence
for Sp1E site, P-203 Sp1EMut, as well as P-203 clone wild-
type, were transfected into MCF7 cells. Mutating Sp1E site
brought the promoter activity down to basal level, sug-
gesting that this site is important for the promoter activity
detected using P-203 construct (Figure 4). Our experi-
ments also revealed that both the Sp1 sites regulated the
MsrB1 transcription. The mutation of either Sp1E or Sp1C
sites produced a decrease in promoter activity (Figure 4).
Moreover, transfection experiments using P-296 Sp1C/
EMut construct, containing mutations of both Sp1 bind-
ing sites, produced a dramatic decrease in the maximal
promoter activity (Figure 4).
Chromatin immunoprecipitation locates Sp1 to the MsrB1 
promoter in vivo
Chromatin immunoprecipitation (ChIP) assays were per-
formed in MCF7 and MDA-MB231 cells to further eluci-
date the mechanisms of MsrB1 promoter regulation. A
promoter MsrB1-specific PCR was performed on sheared
chromatin, which was immunoprecipitated with an Sp1-
specific antibody. As shown in Figure 5, a specific PCR
product was obtained using primers encompassing MsrB1
promoter region -169 to +76. It is interesting to note that
this region contained three Sp1 binding sites (Figure 3).
The MsrB1 promoter PCR fragment was obtained from
both breast cancer cell lines. These results indicated a
direct in vivo interaction of Sp1 with the MsrB1 promoter
in both MCF7 and MDA-MB231 cells. Similar Sp1 levels
were detected by Western blot analysis in both cell lines
(Figure 6).
MsrA does not seem to be involved in MsrB1 expression in 
breast cancer cells
Since MsrA could have a role in MsrB1 transcription [26],
we compared both the MsrA mRNA and protein levels in
high-expressing MsrB1 MCF7 cells and low-expressing
MDA-MB231 cells. As reported in Figure 6, comparable
levels of MsrA transcript were detected in both the breast
cancer cells tested. In addition, similar levels of MsrA pro-
tein were observed. These results suggested that MsrB1
expression was not influenced by the MsrA expression lev-
els.
Effects of DNA demethylation and histone deacetylase 
inhibition on MsrB1 expression
In order to evaluate epigenetic modifications of the MsrB1
promoter as a possible mechanism of MsrB1 silencing,
MDA-MB231 cells were treated with 5-Aza-2'-deoxycyti-
dine (5-Aza-dC). This compound generally showed
reduced levels of DNA methylation and increased expres-
sion of genes silenced by DNA methylation [28]. The
treatment of MDA-MB231 cell line lead to an increase in
MsrB1 mRNA from basal levels as detected by RT-PCR
(Figure 7). Interestingly, treatment with 5-Aza-dC of
MCF7 cells did not have significant effects on the MsrB1
5' – RACE analysis of the MsrB1 gene Figure 2
5' – RACE analysis of the MsrB1 gene. Agarose gel elec-
trophoresis of size marker and MsrB1 5'-RACE product from 
purified total RNA using primer RACE -2 (Table 1). The 5' 
terminal of the sequence of the band from the RACE -2 
primer reaction is reported. The upstream sequence from 
the fragment cloned from the band is in upper case and the 
arrow indicates the transcription start site (+ 1). The open 
reading frame codifying for MsrB1 is in lower case and the 
start codon is in boldface type.
+1
GATTGGTCCTCGGGAG
GGGCGGGGAGGTGGA
CGCGGGTACCGGCGGT
CGTCGGGTCGCAGCGG
CAAGCGCGCTGCGGTT
CCGGTGGCGCCatgtcgtt
ctgcagcttc
134 bp
75 bp
Table 1: Sequences of all the primers used in this study
RACE-1 5'-GAAGCTGCAGAACGACATGG-3'
RACE-1-Hind 5'-CCCAAGCTTGAAGCTGCAGAACGACATGG-3'
RACE-2 5'-CCAACTGACCAAAGGCTGC-3'
P-1403 5'-GAGAGTCTTGATCTTGTCGC-3'
P-1403-Hind 5'-CCCAAGCTTGAGAGTCTTGATCTTGTCG-3'
P-296 5'-CCCAAGCTTGGAGATGCGATTGGACTGG-3'
P-250 5'-CCCAAGCTTGGCCCAGGAGTGGTCC-3'
P-203 5'-CCCAAGCTTAAGATCGTATTGGACCAGCC-3'
P-165 5'-CCCAAGCTTTCCCGGAGGCGGAAGCC-3'
F1MsrB 5'-ATGTCGTTCTGCAGCTTCTTC-3'
R1MsrB 5'-CACACTTGCCACAGGACAC-3'
GAPDHf 5'-CCACCCATGGCAAATTCCATGGCA-3'
GAPDHr 5'-TCTAGACGGCAGGTCAGGTCCACC-3'
forSp1-C 5'-GGACTGGCACCGGGGGTTTTGGCCTTGGGGAAGTGG-3'
revSp1-C 5'-CCACTTCCCCAAGGCCAAAACCCCCGGTGCCAGTCC-3'
forSp1-E 5'-CCAGCCCTGAGGAGGGTTTTGGCCTCCCGGAGGCGG-3'
revSp1-E 5'-CCGCCTCCGGGAGGCCAAAACCCTCCTCAGGGCTGG-3'BMC Molecular Biology 2007, 8:39 http://www.biomedcentral.com/1471-2199/8/39
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expression (data not shown). The effect of 5-Aza-dC on
MsrB1 protein levels was then determined. An induction
of MsrB1 protein by 5-Aza-dC was detected in low-
expressing MsrB1 MDA-MB231 cells (Figure 7). Several
studies suggested a synergistic effect of demethylation and
histone deacetylase inhibition in re-expression of genes
silenced by de novo methylation [29-31]. MDA-MB231
cells were treated with both 5-Aza-dC and trichostatin A
(TSA), the last compound increased the levels of histone
acetylation and expression of at least some target genes
[32,33]. In our experimental conditions, TSA failed to
reactivate MsrB1 in MDA-MB231 cells and did not poten-
tiate the effect of 5-Aza-dC (data not shown). These find-
ings suggested that DNA methylation of the MsrB1
promoter could be a mechanism responsible for the
MsrB1  gene silencing observed in MDA-MB 231 cells.
Sequencing analysis of bisulphite-modified DNA con-
firmed the increase of MsrB1  promoter methylation in
MDA-MB231 compared to MCF-7 cells, MsrB1 gene pro-
moter was indeed hypermethylated at the CG dinucle-
otide within the consensus Sp1-E binding site (Figure 8).
Discussion
In the recent years, the interest in Msr system has focused
on studies demonstrating the importance of this enzy-
matic system on the defence mechanism against oxidative
damage. In particular, recent studies have reported the
role of the Msr system in protecting lens and retinal cells
Effect on the transcriptional activity of site-directed mutagen- esis of the putative Sp1-binding site of the MsrB1 promoter Figure 4
Effect on the transcriptional activity of site-directed 
mutagenesis of the putative Sp1-binding site of the 
MsrB1 promoter. (A) the sequence spanning Sp1- binding 
site (Sp1E) contained in the construct P-203 WT was sub-
jected to site-directed mutagenesis. The mutated construct 
was designed P-203 Sp1EMut. Luciferase reporter activity 
was assessed following transfection into MCF7 cells. Luci-
ferase activity was inhibited by approximately 80% by muta-
tion of Sp1E site. (B) the sequences spanning Sp1-binding 
sites (Sp1C and Sp1E) contained in the P-296 WT construct 
were subjected to site-directed mutagenesis. The constructs 
obtained were designated as P-296 Sp1CMut and P-296 
Sp1EMut. In addition a double mutant containing both muta-
tions was indicated as P-296 Sp1C/EMut. The mutated con-
structs were transiently expressed in MCF7 cells for 
luciferase assays. Luciferase activity was inhibited by approxi-
mately 30% by mutation of Sp1C site; 24% by mutation of 
Sp1E site and by approximately 76% by mutation of both Sp1 
sites (Sp1C/Sp1E). The results are expressed as mean ± S.D. 
of at least five different experiments, in duplicate for each 
construct. Statistically significant differences compared to the 
appropriate WT construct are indicated by *P < 0.005 and 
**P < 0.002.
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Analysis of MsrB1 promoter function in breast cancer cell  lines Figure 3
Analysis of MsrB1 promoter function in breast can-
cer cell lines. (A) MCF7 and MDA-MB231 cells were tran-
siently transfected with five promoter constructs ranging 
from nt -1276 (P-1403) to -38 (P-165) relative to transcrip-
tion start site and extending to nt +127. Promoter fragments 
were inserted into the pGL3-Basic luciferase vector. Luci-
ferase activity was measured as relative light units of firefly 
luciferase normalized with respect to protein concentration. 
Promoter activity is expressed as the magnitude of normal-
ized luciferase activity relative to the pGL3-Basic promoter-
less negative control vector (pGL3). The results are reported 
as mean ± S.D. of at least five different experiments, in dupli-
cate for each construct. (B) a schematic map of the deletion 
constructs excluding each Sp1 binding site is reported (Sp-
1A, Sp-1B, Sp-1C, Sp-1D and Sp-1E).
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against oxidative damage [34-36]. The existence of an
association between increased levels of reactive oxygen
species (ROS) and disturbed activities of enzymatic anti-
oxidants in tumour cells [37] is well known; thus we
began to study the Msr system in cancer cells.
Only a few reports were available on the transcriptional
regulation of MsrA/B  genes. Recently, we reported that
human MsrA gene expression appeared to be different in
several human cancer cell lines and gene promoter analy-
sis showed a cell-specific MsrA transcriptional regulation
[27]. In the present study, we reported evidence indicating
a differential MsrB1 expression in two human cancer cell
lines derived from the same tissue and we elucidated the
mechanisms responsible for the MsrB1 gene expression.
First we cloned the human MsrB1 5'-flanking promoter
region and we provided evidence that this promoter frag-
ment drives expression of luciferase-reporter constructs.
The lack of TATA or CAAT boxes and a high content of
CpG islands in the MsrB1 promoter are typical features of
house-keeping genes. Interestingly, we found five Sp1
binding sites in the MsrB1 promoter and Sp1 was shown
to be important for the transcription of genes with pro-
moters that do not contain TATA boxes [38-40]. Indeed,
we demonstrated the importance of Sp1 sites for MsrB1
promoter activity by site-directed mutagenesis. Three Sp1
binding sites located in the 169 base pair DNA fragment
from the TSS showed the highest promoter activity. The
progressive rise in the promoter activity seems to be
directly correlated with the number of recognition sites
for Sp1, suggesting its functional importance in MsrB1
gene expression. The longest fragment contains five Sp1
boxes but did not retain the highest activity suggesting the
presence of possible cis-elements recognized by negative
modulators.
In the present study, we showed evidence indicating a dif-
ferential pattern of MsrB1 expression in breast cancer cell
lines. Because of ubiquitous expression of Sp1, these sites,
while involved in promoter activity, were not sufficient to
explain the differences in endogenous content of the
MsrB1 gene expression. Moreover, similar levels of Sp1
were detected in these cells by Western blot experiments.
Recently, it was reported that MsrA might have a role in
MsrB1 transcription. In fact, a decrease of MsrB1 in the
MsrA knockout mouse was observed [26]. However, we
found comparable MsrA transcript and protein levels in
both MDA-MB231 and MCF7 cells, suggesting that MsrB1
Expression of MsrA and Sp1 in MCF7 and MDA-MB231 cells Figure 6
Expression of MsrA and Sp1 in MCF7 and MDA-
MB231 cells. (A) MsrA mRNA levels were evaluated after 
RT-PCR of mRNA samples obtained from MCF7 and MDA-
MB231 cells, as described. (B) a representative Western blot 
showing MsrA (26 kDa) and Sp1 (105 kDa) protein levels.
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Chromatin immunoprecipitation assay performed on MCF7,  and MDA-MB231 breast cancer cell lines to evaluate in vivo  Sp1 binding Figure 5
Chromatin immunoprecipitation assay performed on 
MCF7, and MDA-MB231 breast cancer cell lines to 
evaluate in vivo Sp1 binding. Proteins were cross-linked 
to the DNA with formaldehyde and Abs directed against 
RNA-Pol (Ab control) or Sp1 were added to precipitate any 
protein-DNA complexes. The control + lane was DNA that 
had been sonicated and pre-cleared with protein G beads. 
The control-lanes were processed according to the protocol, 
but did not have any Ab added to the samples. PCR were 
performed on isolated DNA using primers encompassing 
MsrB1 promoter region -169 to +76. A schematic map of the 
amplified DNA fragment (245 bp) containing Sp1 binding 
motifs and TSS position is illustrated as well.
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expression was regulated in a different way in our experi-
mental system.
Overall, these findings suggested additional transcrip-
tional mechanisms implicated in the MsrB1 silencing in
MDA-MB231 cells.
Changes in DNA methylation patterns were identified in
cancer and resulted in the silencing of important tumour
suppressor genes involved in differentiation, apoptosis,
cell cycle regulation, DNA repair and metastasis [41,42].
Moreover, several reports indicated that gene silencing
was the consequence of DNA hypermethylation [43-45].
Recently, it was reported that several key genes are
silenced in breast cancer and these events seemed to be
linked to epigenetic modifications [46].
Consistent with an important role of DNA methylation in
MsrB1 silencing, incubation of MDA-MB231 cells with 5-
Aza-dC resulted in clearly detectable levels of both MsrB1
mRNA and protein. On the other hand, treatment of
MDA-MB231 cells with TSA did not induce MsrB1 expres-
sion and there was no synergistic effect of TSA and 5-Aza-
dC on MsrB1 expression. These findings suggested that
transcriptional repression by DNA methylation was
unlikely to depend upon a TSA-sensitive histone deacety-
lase. These observations are consistent with the recent
reports studying the regulation of the hypermethylated
genes RFC, HPRT and others. In these studies, the treat-
ment of 5-Aza-dC induced the expression of these hyper-
methylated genes, whereas TSA treatment did not induce
similar changes [47,48].
Previous studies reported that DNA methylation
decreased Sp1 binding affinity to the respective promoter
region [49,50]. In contrast, we show in this report, using
ChIP experiments, that Sp1 binds the MsrB1 promoter
region in both high-expressing MCF7 and low-expressing
MDA-MB231 breast cancer cells. These findings suggest
Analysis of MsrB1 CpG island promoter methylation status in  MCF7 and MDA-MB231 cells Figure 8
Analysis of MsrB1 CpG island promoter methylation 
status in MCF7 and MDA-MB231 cells. Shown are 
results of bisulfite genomic sequencing of 20 individual 
clones. The x axis of the graph indicates the CpG doublet 
position in the 5'-flanking region of MsrB1 with respect to the 
start site of transcription; the y axis indicates the percentage 
of the subclones that were methylated.
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that Sp1 binding affinity to the MsrB1 promoter is not
inhibited by DNA methylation. Similar data have been
recently reported for the LHR promoter [51] and for the
CLDN4 promoter [31].
A proposed mechanism to explain transcriptional inacti-
vation from promoter methylation is based on the finding
that methyl-CpG-binding proteins bind methylated DNA
[52] and these proteins can then recruit a variety of tran-
scriptional repressors [53-56]. Whether these transcrip-
tional repressors are responsible to affect the MsrB1
expression in MDA-MB231 cells is still uncertain.
The epigenetic silencing of genes whose proteins function
to attenuate oxidative free radicals, e. g., GSTP1, have been
described in prostate cancer [57]. The epigenetic mediated
loss of expression of antioxidant enzymes would create
conditions favourable to both DNA base damage and
accelerated proliferation. Obviously, more research is
needed to postulate a possible MsrB1 involvement in met-
astatic process.
Conclusion
In the present work, we showed that: (1) Sp1 is essential
for the human MsrB1 promoter activity; (2) despite hav-
ing all of the usual characteristics of a ubiquitously
expressed "housekeeping" gene, MsrB1 is regulated differ-
ently among breast carcinoma cells; and (3) treatment
with DNA methyltransferase inhibitor 5-Aza-dC induced
MsrB1  gene expression in the highly metastatic MDA-
MB231 cells. On the basis of these findings, we conclude
that epigenetic changes are involved in MsrB1 silencing.
Methods
Cell cultures
Human breast cancer cells MDA-MB231 and MCF7 were
grown in a humidified atmosphere containing 5% CO2 at
37°C in DMEM containing high glucose (4.5 g/liter at 25
mM) and supplemented with 50 units/ml penicillin, 50
mg/ml streptomycin, and 10% (vol/vol) FBS. For 5-Aza-
2'-deoxycytidine (5-Aza-dC) and trichostatin A (TSA)
treatment, cells were seeded at low density in a 100 mm
tissue culture dish and maintained for a total 96 h. The
former was added after 24 h in culture, and the cells were
incubated with this drug for a total 72 h. Culture medium
supplemented with 5-Aza-dC 10 µM was exchanged every
24 h. The latter was added to the media after 48 h of incu-
bation and cells were then incubated with TSA for 24 h.
Determination of 5'-terminal cDNA sequence
To map the transcription start site (TSS) of MsrB1, an RNA
ligase-mediated rapid amplification of 5' end (RLM-
RACE) strategy was used to obtain the full-length cDNA
sequence at the 5' end, using a GeneRacerTM (Invitrogen)
kit. A detailed protocol is available from the authors upon
request. Briefly, five micrograms of total RNA from MCF7
cells were used to prepare 5'-racing cDNA as previously
described [27]. RACE-1 primer (Table 1) was used in
reverse transcription of adapter ligated mRNAs. The first-
strand cDNA was amplified using the reverse gene-specific
primer RACE-1 and the GeneRacerTM 5' Primer. An aliq-
uot of PCR products was used as the template for a nested
reaction using the RACE-2 reverse gene-specific primer
and the GeneRacerTM 5' Nested Primer. PCR products
were analyzed by 3% agarose, cloned into pCR4-TOPO
vector and analyzed by sequencing.
Construction of luciferase deletion plasmids
Genomic DNA was prepared from the MCF7 cells using
Wizard Genomic DNA Purification Kit (Promega). Two
oligonucleotides, P-1403 and RACE-1, were designed
(Table 1), on the basis of genomic DNA sequence of 5'-
flanking region of the MsrB1 gene, to amplify a portion of
DNA starting -1276 bp upstream of the identified tran-
scription start site (+1). In addition to the template
(genomic DNA) and primers P-1403 and RACE-1, the
reaction mixture contained 0.2 mM dNTPs, Pfu  DNA
polymerase buffer and 5 units of Pfu DNA polymerase
(Promega), and was subjected to 35 cycles of amplifica-
tion (60 s at 94°C, 60 s at 56°C, and 120 s at 72°C). The
PCR product was recovered from low-melting agarose gel
and used as template in PCR reaction. In this PCR ampli-
fication we used the primers P-1403-Hind and RACE-1-
Hind tailed at 5' with a Hind III restriction endonuclease
recognition sequence (Table 1). The PCR product was
loaded on 1.5% low melting agarose gel, recovered from
the gel, purified and ligated into pGL3-basic reporter vec-
tor Hind III digested and dephosphorylated; the resulting
plasmid was designated P-1403. Insertion in the pGL3-
basic reporter vector and the correct orientation were ver-
ified by DNA sequencing. A nested set of MsrB1 promoter
fragments was created by PCR amplification using the oli-
gonucleotide sequences shown in Table 1 (P-296, P-250,
P-203 and P-165) and P-1403 as template. PCR amplifica-
tion products were loaded on 2% low melting agarose gel,
recovered from the gel, purified and ligated into pGL3-
Basic reporter vector Hind III digested. The resulting plas-
mids, P-296, P-250, P-203 and P-165, were analyzed by
DNA sequencing to ensure the fidelity of amplification
and the correct orientation.
Site-directed mutagenesis
The 296 bp (-169 bp to +127 bp) and the 203 bp (-76 bp
to + 127 bp) promoter regions incorporated into the P-
296 construct and into the P-203 construct respectively
were subjected to site-directed mutagenesis, to eliminate
cores of Sp1-C and SP1-E binding sites, using the Quick
Change Site-Directed Mutagenesis Kit (Stratagene). The
mutagenic primers (forSp1-C and revSp1-C) containing
the mutation of Sp1-C were reported in Table 1. BothBMC Molecular Biology 2007, 8:39 http://www.biomedcentral.com/1471-2199/8/39
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primers annealed to the same target sequence on opposite
strands of P-296. Site-directed mutagenesis was per-
formed according to the manufacturer and the resulting
plasmid was designated P-296Sp1CMut. The two muta-
genic primers containing the mutation of Sp1-E were also
reported in Table 1. Both primers (forSp1-E and revSp1-E)
annealed to the same target sequence on opposite strands
of P-296, P296 Sp1CMut and P-203. The site-directed
mutagenesis was performed as described by the manufac-
turer. The resulting plasmids were designated P-296
Sp1CMut, P-296 Sp1EMut, P-296Sp1C/E Mut and P-203
Sp1EMut and were confirmed by DNA sequencing.
Transient transfections and luciferase assays
MDA-MB231 cells and MCF7 cells were plated in 12-well
plates 24 h before transfection. The day of transfection,
cells were washed twice with PBS solution and replaced
with DMEM medium containing 1% FBS (not containing
penicillin-streptomycin). Cells were transfected with 0.8
µg of P-1403 (the longest luciferase construct) and equi-
molar amounts for other plasmids were used. After 2 h of
incubation at 37°C, the transfection solution was with-
drawn and replaced with the complete medium described
above, and cultivated for an additional period of 24 h at
37°C. Transfection were performed in duplicate, and
repeated at least five times. Measurement of luciferase
activity was performed 24 h after transfection using the
Luciferase Assay Kit (Promega) according to the manufac-
turer's protocol. Each lysate was measured twice. Luci-
ferase activities were normalized with respect to protein
concentration in each extract to correct for transfection
efficiency, and the reporter gene expression was expressed
as relative light units. The luciferase activity of each con-
struct was compared with that of the promoterless pGL3
Basic vector.
RT-PCR
RT-PCR was performed using 1 µg of total RNA extracted
from MDA-MB231 and MCF7 cell lines as described
above. Reverse transcription reactions were performed
using M-MLV Reverse Transcriptase (Sigma) and polydT
primers, as recommended by the manufacturer. F1MsrB
and R1MsrB primers (Table 1) were designed to amplify a
portion of 200 bp of MsrB1 gene in PCR amplification
reaction. In addition to primers and 2 µl of template
(cDNAs obtained as reported above) the 50 µl reaction
mixture contained 0.2 mM dNTPs, Taq DNA polymerase
buffer and 5 units of Taq Gold DNA polymerase (Applied
Biosystem, PE), and was subjected to 10 min at 95°C fol-
lowed by 24 cycles of amplification (60 s at 95°C, 60 s at
54°C, and 60 s at 72°C). PCR products were verified by
DNA sequencing. To provide further confidence in the
data, 598 bp of glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was amplified by 21 cycles of amplifica-
tion using primers GAPDHf and GAPDHr (Table 1). MsrA
amplification was obtained using MsrAfor 5'-GGAAT-
GGGATGTTTCTGGG-3' and MsrArev 5'-TGAGCAGACT-
TCTTTATAAGTA-3' primers. The templates used in PCR
reactions were the same cDNAs obtained as described
above. The abundance of PCR products was measured by
densitometric scanning of the ethidium bromide-stained
agarose gels using Chemi Doc System, and the cDNA frag-
ments corresponding to each amplified gene was com-
pared between MDA-MB231 and MCF7 cells. Each data
point was normalized using the quantity of GAPDH
mRNA.
Western blot analysis
Protein extracts were obtained from 80% confluent MDA-
MB231 cells and MCF7 cells, using Passive Lysis Buffer
(Promega). Crude extracts (40 µg) were analysed by SDS/
PAGE on 15% (w/v) polyacrylamide gels. Proteins were
transferred electrophoretically to nitrocellulose (for 120
min at 0.3 A) using an immunoblot transfer apparatus
(Bio-Rad). After transfer, the nitrocellulose was incubated
for 180 min at room temperature in 10% (w/v) non fat
milk in Tris-buffered saline (TBS; 500 mM NaCl and 20
mM Tris/HCl, pH 7.5), supplemented with 0.05% (v/v)
Tween 20, to block non-specific binding. The blot was
incubated overnight at 4°C with 10% non fat milk in TBS,
supplemented with 0.05% (v/v) Tween 20, containing
mouse monoclonal anti-MsrB (Abcam Inc.) at a dilution
of 1:1000. After three washes with TBS containing 0.05%
(v/v) Tween 20, the blot was incubated for 60 min at
room temperature with peroxidase-conjugated goat anti-
mouse immunoglobulin (Calbiochem) diluted at 1:2000
in 10% non fat milk in TBS, supplemented with 0.05% (v/
v) Tween 20. The blot was again washed three times with
TBS containing 0.05% (v/v) Tween 20. Antibodies were
visualized using a chemiluminescence detection system
(Western Blotting Luminol Reagent, Santa Cruz Biotech-
nology). Western blotting analysis was also performed
using rabbit polyclonal antiserum anti-MsrA produced in
our laboratory as previously described [27] and rabbit
polyclonal anti-Sp1 (Santa Cruz, sc-14027).
Chromatin immunoprecipitation assay
To study protein/DNA interactions we used ChIP-IT™ Kit
(Active Motif). A detailed protocol is available from the
authors upon request. Briefly, MCF7 and MDA-MB231
cells were crosslinked for 10 min at room temperature by
adding Fixation solution. Cells were scraped in presence
of Cell Scraping Solution. Nuclei release was obtained
with dounce homogenizer. The cells were centrifuged at
5000 rpm for 10 min at 4°C to pellet the nuclei. The
nuclei pellet was resuspended in Shearing Buffer, supple-
mented with protease inhibitors and sonicated using ten
pulses of 20 s. After centrifugation, the supernatant was
diluted in ChIP buffer and pre-cleared with Protein G
beads for 2 hours at 4°C. An aliquot (10 µl) of pre-clearedBMC Molecular Biology 2007, 8:39 http://www.biomedcentral.com/1471-2199/8/39
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chromatin was stored at -20°C as "Input DNA". The
supernatant was divided into three aliquots. No antibod-
ies were added to one aliquot (negative control), and
either RNA pol II antibody or Sp1-specific antibody
(Santa Cruz, sc-14027 X) was added to the others two
aliquots and they incubated overnight at 4°C on a rotat-
ing wheel. Protein G beads were added into each of the
antibody/chromatin incubations and the tubes were incu-
bated on a rotator for 1.5 hours at 4°C. Immunoprecipi-
tated DNA was eluted from the washed Protein G beads
and cross-linking was reversed by heating the elutes at
65°C overnight. The elutes were then digested with pro-
teinase K at 42°C for 2 hours. DNA was purified using
mini-columns provided with the ChIP-IT™ Kit. The MsrB1
promoter region was amplified by PCR using 5-
GGCCCAGGAGTGGTCC-3' (forward) and 5'-CCAACT-
GACCAAAGGCTGC-3'(reverse) primers.
DNA methylation analysis of the MsrB1 gene
Genomic DNA (0.5 µg in a volume of 100 µl) was dena-
turated in 0.2 M NaOH at 37°C for 10 min and incubated
with 3 M sodium bisulfite at 55°C for 16 h. After bisulfite
treatment, DNA was desalted using the Wizard DNA
Clean-up System (Promega), ethanol-precipitated,
washed, and resuspended in TE (100 µl). Bisulfite-modi-
fied DNA was amplified by PCR with a primer set
designed to detect both methylated and unmethylated
promoter regions of the MsrB1 gene. Primer sequences for
the unmethylated reaction were 5'-GGCCCAGGAGT-
GGTCC-3' (forward) and 5'-GAAGCTGCAGAACGA-
CATGG-3' (reverse), and for the methylated reaction were
5'- GGTTTAGGAGTGGTTTTAAGGAG-3' (forward) and
5'-AAAACTACAAAACGACATAA-3' (reverse). Primers
were located at -123 (forward) and +127 (reverse) from
the transcription start site. Purified PCR products were
cloned into the TOPO-TA vector (Invitrogen) by using the
manufacturer's standard protocol. Twenty clones were
sequenced from each sample.
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